Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.
Cantrixil is being developed as a new treatment option for women with later-stage ovarian cancer who received limited benefit from existing chemotherapy. The drug could enable intraperitoneal (IP) chemotherapy to again become a viable treatment option in patients where it has become ineffective due to resistance.
In this interview with NDF Research’s Senior Analyst Stuart Roberts, Kazia’s CEO Dr James Garner discusses:
- where the study is up to and what will happen next
- how a dose escalation study works
- patient recruitment
- early results from the study so far
